A number of firms have modified their ratings and price targets on shares of Sorrento Therapeutics (NASDAQ: SRNE) recently:

  • 8/10/2017 – Sorrento Therapeutics was given a new $7.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 8/4/2017 – Sorrento Therapeutics is now covered by analysts at Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $7.00 price target on the stock.
  • 8/3/2017 – Sorrento Therapeutics is now covered by analysts at UBS AG. They set an “outperform” rating and a $7.00 price target on the stock.
  • 8/3/2017 – Sorrento Therapeutics is now covered by analysts at Roth Capital. They set a “buy” rating and a $7.00 price target on the stock.
  • 7/4/2017 – Sorrento Therapeutics was given a new $20.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 6/27/2017 – Sorrento Therapeutics was given a new $20.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 6/17/2017 – Sorrento Therapeutics had its “buy” rating reaffirmed by analysts at FBR & Co.

Sorrento Therapeutics, Inc. (SRNE) opened at 1.65 on Wednesday. The firm has a 50-day moving average of $1.93 and a 200-day moving average of $2.86. The company’s market capitalization is $126.29 million. Sorrento Therapeutics, Inc. has a 52 week low of $1.50 and a 52 week high of $8.35.

In other Sorrento Therapeutics news, insider Henry Ji acquired 29,001 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The stock was purchased at an average price of $1.81 per share, for a total transaction of $52,491.81. Following the completion of the acquisition, the insider now owns 139,776 shares of the company’s stock, valued at approximately $252,994.56. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.00% of the stock is currently owned by insiders.

Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.

Receive News & Ratings for Sorrento Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.